A prospective single‐center, single‐arm, open‐label, phase II study of sintilimab and anlotinib combined with chemotherapy in neoadjuvant treatment of resectable esophageal cancer

Hongtao Duan,Zhaoyang Wang,Lili Cao,Yifang Zhu,Liping Tong,Xiaolong Yan

DOI: https://doi.org/10.1111/1759-7714.15312

IF: 3.223

2024-05-22

Thoracic Cancer

Abstract:This study focused on the neoadjuvant therapy of immune checkpoint (sintilimab) and receptor tyrosine kinase (anlotinib) inhibition combined with chemotherapy in resectable esophageal cancer. To the best of our knowledge, the first results of sintilimab and anlotinib combined with chemotherapy in neoadjuvant treatment of resectable esophageal cancer are reported. Out of the 34 screened patients, 17 were successfully enrolled in the study, and 14 completed the entire treatment process. The postoperative pCR rate was 35.3% (6/17 patients). However, two patients experienced death Clavien–Dindo classification identified the incidence of grade 3 or higher complications after the surgical treatment as 78.6% (11/14). Specifically, postoperative anastomotic leakage was observed in 57.1% (8/14) of patients. This finding suggests that compared to neoadjuvant chemotherapy, sintilimab and anlotinib combined with chemotherapy demonstrated improved postoperative pCR rates. However, it did not show significant improvement compared to immunochemotherapy. It is essential to exercise caution when using this treatment approach in patients with esophageal cancer as it might increase postoperative complications, especially anastomotic leakage. Background Antiangiogenic treatment and immunochemotherapy effectively treat patients with advanced esophageal cancer. However, there remains a dearth of studies concerning neoadjuvant therapy for resectable esophageal cancer. Methods The study focused on patients with T2–4NxM0 resectable esophageal carcinoma. Neoadjuvant treatment involved administering anlotinib (10 mg orally, once a day, 2 weeks on and 1 week off) for antiangiogenesis and sintilimab (200 mg) and chemotherapy for three cycles. Surgical treatment was performed 4–6 weeks after the last chemotherapy cycle was completed. The primary endpoints assessed were pathological complete response (pCR) and safety. Results Out of the 34 screened patients, 17 were successfully enrolled in the study, and 14 completed the entire treatment process. The pCR was 35.3% (6/17). However, two patients experienced mortality. The occurring rate of grade 3 or higher complications after the surgery was 78.6% (11/14) according to Clavien–Dindo classification. Specifically, anastomotic leakage was observed in 57.1% (8/14) of the patients. Conclusion Compared to neoadjuvant chemotherapy, the current regimen demonstrated improved pCR. However, it did not show significant improvement compared to immunochemotherapy. It is essential to exercise caution when using this treatment approach in patients with esophageal cancer as it might increase postoperative complications, especially anastomotic leakage.

oncology,respiratory system